Zimmer Biomet (ZBH) is a publicly traded Healthcare sector company. As of May 20, 2026, ZBH trades at $85.64 with a market cap of $16.47B and a P/E ratio of 24.44. ZBH moved -0.94% today. Year to date, ZBH is -7.85%; over the trailing twelve months it is -10.46%. Its 52-week range spans $79.12 to $114.72. Analyst consensus is neutral with an average price target of $97.08. Rallies surfaces ZBH's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Which politicians traded ZBH stock?
Recent politician trading activity in ZBH includes disclosures from Rob Bresnahan, Julie Johnson, and Ro Khanna. Rallies tracks purchase and sale disclosures, transaction dates, owners, reported amounts, and post-trade performance context.
ZBH Key Metrics
Key financial metrics for ZBH
Metric
Value
Price
$85.64
Market Cap
$16.47B
P/E Ratio
24.44
EPS
$3.56
Dividend Yield
0.24%
52-Week High
$114.72
52-Week Low
$79.12
Volume
2.03M
Avg Volume
0
Revenue (TTM)
$8.23B
Net Income
$705.10M
Gross Margin
69.70%
Congressional Trades in ZBH
Rob Bresnahan sale ZBH on May 15, 2025 (amount: $15.00K).
Julie Johnson sale ZBH on Feb 11, 2025 (amount: $15.00K) for Joint.
Ro Khanna purchase ZBH on Jun 12, 2024 (amount: $15.00K) for Spouse.
Recent politician trading activity in ZBH includes disclosures from Rob Bresnahan, Julie Johnson, and Ro Khanna. Rallies tracks purchase and sale disclosures, transaction dates, owners, reported amounts, and post-trade performance context.
Does Rallies track congressional trades in ZBH?
Yes. Rallies tracks politician and congressional stock disclosures for ZBH, including reported purchases, sales, dates, owners, and trade amounts when available.
Is ZBH research on Rallies investment advice?
No. Rallies provides research, data, and educational context for ZBH. It does not provide personalized investment advice.
